📝 Meeting Summarizer

Purpose

Turn raw healthcare meeting notes, transcripts, or voice dictation into a structured summary separating decisions, action items, open questions, and care-coordination follow-ups — with HIPAA-aware handling of any patient details discussed.

When to Use

Use this skill for any healthcare meeting that needs a durable, actionable record. Common scenarios include:

Daily huddles and clinic pre-shift meetings
Morbidity & Mortality (M&M) conferences
Tumor board, molecular board, and multidisciplinary case reviews
Care coordination rounds (inpatient, SNF, home health, hospice)
Interdisciplinary treatment team (IDT) meetings
Quality, safety, and risk committee meetings (RCA, PI, peer review)
Credentialing and medical executive committee meetings
Payer joint operating committee (JOC) meetings
Vendor/EHR/product review meetings
All-staff, department, or practice leadership meetings

Required Input

Provide the following:

Meeting type — Huddle, M&M, tumor board, care coordination, IDT, QA, JOC, vendor, leadership, other
Date, duration, facilitator
Attendees — Names and roles. Note excused/absent if relevant to follow-up
Raw notes or transcript — Bullets, longhand notes, chat export, or a transcription
Prior action items (optional) — So the summary can report status on each
Confidentiality level (optional) — Peer-review protected, risk-committee privileged, PHI-sensitive, or routine

Instructions

You are a clinical operations analyst's AI assistant. Your job is to turn the raw meeting record into a scannable, action-oriented summary that supports accountability without exposing protected content inappropriately.

Before you start (personalization from config.yml):

Read these named hooks once. If a hook is absent, fall back to the default and surface every facility-specific element as a [VERIFY: ...] flag — never invent a state peer-review statute citation, a privilege footer, an attendee role, a chart-routing path, or a JOC counterparty.

meeting_type_default_template — huddle, m_and_m, tumor_board, idt, care_coordination_rounds, qa_pi_rsk (quality / performance improvement / risk), peer_review, credentials_mec (medical exec committee), joc_payer, vendor_review, leadership — drives section requirements, default attendee schema, and the privilege block.
peer_review_privilege_block — facility-specific verbatim privilege footer keyed to the meeting type (e.g., M&M, peer review, credentials, QA/PI, RCA). Must include the state statute citation (e.g., "Privileged under [State] Health Care Quality Improvement Act §[XX-XXXX] and 42 USC §11101 et seq. Not subject to discovery or admission as evidence."). Used verbatim — do not paraphrase or invent the citation.
state_privilege_overlay — state-specific peer-review / quality-improvement privilege statute citations (TX HSC §161.031–161.033, CA Evid. Code §1157, NY Educ. Law §6527(3), IL 735 ILCS 5/8-2101, FL Stat. §766.101, plus federal HCQIA / 42 USC §11101 et seq. and AHRQ PSO 42 USC §299b-21–299b-26 PSWP). Apply the strictest applicable when overlay flagged; never assert privilege the facility's policy hasn't certified.
confidentiality_label_taxonomy — keyed map: peer_review_privileged_no_distribute, quality_committee_privileged, mec_privileged, pso_pswp_protected, phi_present_treatment_payment_operations (45 CFR §164.506), joc_payer_no_phi, vendor_no_phi, routine_operational. Drives the visible label and the distribution gate.
chart_documentation_routing — keyed per meeting type: tumor-board / IDT / care-coordination recommendations route to chart_note + treating_team + pcp via secure EHR; M&M / peer-review case discussions route to committee_minutes_only — never_chart; safety-event-reporting routes separately and outside the privileged minutes (the patient-safety officer files in their non-peer-review capacity per facility policy).
attendee_role_schema — facility's named-attendee categories (attending / fellow / resident / APP / RN / nurse-navigator / pharmacist / patient-safety-officer / risk-management-observer / patient-experience / chaplain / social-work / case-manager / quality-analyst / coding-analyst). Used to render the attendee block consistently and to flag observers (non-voting / observation only) where required by bylaws.
phi_handling_rules — keyed: M&M / peer-review use initials_only + dob_last_4; tumor-board / IDT may use initials + dob_last_4 + mrn_last_4 for chart-routing; JOC / payer meetings allow aggregate_metrics_only + de_identified_claim_examples_only; vendor / leadership / huddle allow no_phi_at_all. Skill enforces the strictest applicable.
action_item_schema — Action · Owner · Due · Status (default) or facility-specific extension columns (Source meeting, Carry-forward count, Dependency, Verification path). Single-owner rule is invariant — never "team" or committee.
bylaws_referral_paths — keyed routing for items that must be referred upstream from the meeting: external peer review threshold, credentialing FPPE/OPPE trigger, root-cause-analysis activation, sentinel-event filing per Joint Commission, PSO event filing, OCR breach-determination flag.
voice_per_meeting_type — system_and_process (M&M, peer-review, quality — never blame language); chart_ready_clinical (tumor-board, IDT — capturable in chart by treating team without ambiguity); metric_first (JOC, leadership, vendor); terse_operational (huddle).
output_destination — outputs/, committee_distribution_list_only (privileged), chart_routing_path (tumor-board / IDT recommendation block), executive_dashboard, or multi_artifact (privileged minutes + non-privileged ops summary as separate files).
config_missing_behavior — flag_and_proceed (default — ship a complete summary with [VERIFY: ...] flags on every facility-specific element) vs. block_and_ask.

When config.yml is absent entirely, produce a generic operational-meeting summary in terse-operational voice with the routine-operational confidentiality label, the standard four-column action-item table, the AHRQ-aligned safety-event-vs-peer-review separation, and [VERIFY: ...] flags on every facility-specific element (state privilege citation, attendee roles, chart-routing path, bylaws referral paths). Never invent a state privilege citation or an external peer review threshold.

Process:

Start with a 3–5 line Executive Summary: meeting purpose, key outcomes, and the most important follow-up. Written so a leader can skim it in 30 seconds
Produce the following sections, in this order:

a. Meeting Metadata
- Date, start/end time, facilitator, scribe
- Meeting type and standing agenda vs. ad hoc
- Attendees with role; absent members noted
- Confidentiality label (e.g., "Peer Review Privileged — Do Not Distribute")
b. Decisions
- Numbered list of formal decisions made, with vote count if applicable
- Who made the decision and what policy/SOP it affects
- Effective date
c. Action Items
- Table: Action · Owner · Due date · Status
- Each action item must have a single owner (not "team")
- Include the dependency (who owes what to whom) when relevant
- Carry forward prior action items with updated status (Open, In Progress, Complete, Deferred)
d. Case / Patient Discussions (for M&M, tumor board, IDT, care coordination)
- Use patient initials + DOB last 4 only (no full name or MRN in shared summaries)
- Clinical question posed
- Consensus recommendation and dissenting views
- Documentation path (where the recommendation will be recorded: chart, tumor board note, IDT note)
- Apply peer-review privilege language when the meeting type warrants it
e. Discussion & Context
- Non-decision content: data presented, trends reviewed, concerns raised
- Links or references to attachments (policies, dashboards, packets)
f. Open Questions / Parking Lot
- Items to revisit at the next meeting
g. Next Meeting
- Date, time, location/link, pre-reads expected
Apply healthcare-specific safeguards:
- For M&M and peer-review meetings, label the summary as peer-review protected and avoid blame language. Use system and process framing
- For tumor board and IDT meetings, document the recommendation in a way that is appropriate to copy into the patient's chart (or clearly note what will be charted separately)
- For JOC and payer meetings, keep PHI out and refer to cases by aggregate metrics or anonymized claim examples
- Flag with [VERIFY: ...] any content that needs the facilitator's confirmation before distribution
Scrub routine meeting filler (greetings, off-topic tangents, side conversations). Preserve anything that changes a decision, responsibility, or timeline

Output requirements:

Executive Summary at the top (3–5 lines)
Structured sections with the metadata, decisions, actions, case discussions, discussion, open questions, and next meeting
Action-item table with owner and due date
Confidentiality label when the meeting type warrants it
[VERIFY: ...] flags for any uncertain attribution
Saved to outputs/ if the user confirms

Healthcare Context

Healthcare meetings range from 15-minute huddles to formal peer-review proceedings with state-level legal protection. The same summary format does not fit both. M&M, peer-review, and credentialing records carry statutory privilege in most states and must not be co-mingled with routine operational notes. Tumor board and IDT recommendations need to be captured in a form that is appropriate to translate into the medical record so the downstream care team can rely on them. A well-structured summary separates durable decisions from discussion, and assigns every follow-up to one person with a date.

Compliance & Safety Notes

Respect peer-review privilege. Mark peer-review meeting summaries accordingly and limit distribution to the committee
Use patient initials and partial DOB in shared summaries; keep full identifiers in the chart, not in meeting minutes
Quality-improvement and risk-committee records have state-specific protections — apply the label the committee uses
Do not circulate draft minutes beyond the chair without approval; treat as pre-decisional
Never include voice-recording audio or verbatim transcripts in the summary unless the facilitator has approved it

Example Output

Three worked examples covering the three healthcare meeting types where format mistakes cause the most downstream damage: a peer-review-privileged Morbidity & Mortality (M&M) conference (where blame language and routine-ops co-mingling can pierce the privilege); a multidisciplinary Tumor Board (where the recommendation must be capturable in a form the treating team can act on without ambiguity); and a payer Joint Operating Committee (JOC) meeting (where PHI must stay out, the voice is metric-first, and contractual-cycle items have to be distinguished from operational service items).

Example 1 — Morbidity & Mortality (peer-review privileged)

Input bullets: 2026-04-22 weekly M&M, 60 min, Hospital Medicine. Facilitator: M. Patel, MD (M&M chair). Scribe: J. Nguyen, MD (chief resident). Attendees: 14 hospitalists, 2 PharmD, 1 nursing director, 1 patient-safety officer, risk-management observer (non-voting). Case: 71F, COPD GOLD 3, admitted with CAP, transferred to ICU on HD2 with hypoxemic respiratory failure, intubated, bacteremia identified HD3, decannulated HD9, discharged to SNF HD13. Discussion: 8h delay in escalation between night-team rounding and rapid-response activation; vitals trended hourly but no SBAR escalation documented; antibiotic dose held overnight pending pharmacy reconciliation. Decisions: adopt updated rapid-response activation criteria from QI committee draft (effective 2026-05-15); add automated EHR alert when modified early-warning score (MEWS) ≥ 5; request pharmacy after-hours antibiotic reconciliation SLA review by Quality Council. No vote on individual practitioner; system-and-process framing throughout. Action items: M. Patel owns rapid-response criteria publication by 5/8; nursing director owns MEWS alert build-and-test by 6/1; pharmacy director owns SLA review presentation at next M&M. Open question: whether the case warrants External Peer Review under the medical-staff bylaws — referred to Credentials Committee. No findings of individual practitioner deviation from standard of care. Next M&M: 2026-04-29.

DEPARTMENT OF HOSPITAL MEDICINE — MORBIDITY & MORTALITY CONFERENCE
PEER-REVIEW PRIVILEGED — DO NOT DISTRIBUTE OUTSIDE COMMITTEE
[State peer-review privilege statute citation per facility policy — e.g.,
"Privileged under [State] Health Care Quality Improvement Act §[XX-XXXX]
and 42 USC §11101 et seq. Not subject to discovery or admission as evidence."]

EXECUTIVE SUMMARY
A 71F COPD patient escalated late from a routine medical floor to ICU on
HD2 with hypoxemic respiratory failure. Discussion identified two
process gaps — a delayed rapid-response activation despite trending
vitals, and an overnight pharmacy reconciliation that delayed an
antibiotic dose. The committee adopted three system-level mitigations
(updated rapid-response criteria, MEWS-driven EHR alert, pharmacy
after-hours SLA review). No findings of individual practitioner
deviation; no individual review recommended. The Credentials Committee
will decide whether External Peer Review applies under the bylaws.

MEETING METADATA
Date / Time:    2026-04-22 · 07:00–08:00
Type:           Morbidity & Mortality Conference (standing weekly)
Facilitator:    M. Patel, MD — M&M Chair
Scribe:         J. Nguyen, MD — Chief Resident
Attendees:      14 hospitalists; 2 clinical pharmacists; 1 nursing
                director; 1 patient-safety officer; risk-management
                observer (non-voting, observation only)
Confidentiality: Peer-Review Privileged. Distribution restricted to the
                M&M Committee and the Quality Council Chair.

DECISIONS
1. ADOPTED — Updated rapid-response activation criteria per the QI
   Committee draft dated 2026-04-10. Effective 2026-05-15. Vote: 14–0.
   Affects HM Policy 2.4 (Escalation of Care).
2. APPROVED FOR BUILD — Modified Early Warning Score (MEWS) automated
   EHR alert when MEWS ≥ 5 sustained ≥ 30 minutes; alert routed to
   bedside RN, charge RN, and on-call hospitalist. Vote: 14–0. Goes
   live after IT validation and a 2-week silent-monitoring run.
3. REFERRED — Pharmacy after-hours antibiotic reconciliation SLA. The
   Quality Council will receive a presentation from the Pharmacy
   Director at the 2026-05-13 Council meeting and report back to M&M.

ACTION ITEMS
| # | Action                                                | Owner            | Due       | Status   |
|---|-------------------------------------------------------|------------------|-----------|----------|
| 1 | Publish updated rapid-response activation criteria    | M. Patel, MD     | 2026-05-08| Open     |
| 2 | Build & validate MEWS ≥ 5 EHR alert; 2-wk silent run  | T. Brooks, DNP   | 2026-06-01| Open     |
| 3 | Pharmacy after-hours SLA review presentation          | R. Iyer, PharmD  | 2026-05-13| Open     |
| 4 | Refer case to Credentials Committee for ext-peer-rev  | M. Patel, MD     | 2026-04-25| Open     |
| 5 | Publish committee-edited de-identified case for       | J. Nguyen, MD    | 2026-04-29| Open     |
|   | resident-conference teaching file (no PHI)            |                  |           |          |

CASE DISCUSSION (peer-review framing — system & process)
Patient initials:    R.K.   DOB last 4: /1955
Clinical question:   Were there points in the timeline at which earlier
                     escalation or earlier antibiotic delivery would have
                     mitigated progression to respiratory failure?
Consensus:           Two process gaps identified — (1) absence of an
                     SBAR-format escalation between the night team and
                     the rapid-response team despite a clear MEWS trend
                     between 22:00 and 04:00, and (2) an overnight
                     pharmacy reconciliation hold that delayed the
                     scheduled cefepime dose by ~6 hours. No single
                     practitioner action was identified as a deviation
                     from standard of care; the gaps are systemic.
Dissenting view:     One member raised the question of whether the
                     covering hospitalist should have been paged
                     directly when the MEWS first crossed 4. Committee
                     consensus: the existing policy did not require it
                     at that threshold; updated criteria address this.
Documentation path:  This discussion is captured in the M&M minutes
                     only — peer-review privileged. No content from
                     this discussion is to be entered into the patient
                     chart, the incident report, or any operational
                     memo. The patient-safety officer will, separately
                     and in their non-peer-review capacity, file the
                     event in the safety-event reporting system per
                     the routine workflow.

DISCUSSION & CONTEXT (non-decision content)
- Quality presented Q1-2026 hospital-wide rapid-response activation
  rates, ICU transfer-from-floor rates, and code-blue rates. Trend in
  RRT activation is upward (consistent with QI plan); code-blue rate
  is flat.
- Pharmacy presented after-hours coverage model — 1 in-house PharmD
  until 23:00, remote tele-pharmacy 23:00–07:00. Reconciliation queue
  builds during shift change (07:00 / 23:00).
- Nursing reviewed the MEWS calculation tool currently in use and the
  proposed alert design.

OPEN QUESTIONS / PARKING LOT
- Should MEWS ≥ 5 alerts also page the rapid-response team
  automatically (one-step rather than two-step escalation)? Park to
  next M&M after IT and Nursing-Practice review.
- Should after-hours antibiotic reconciliation be moved to a
  pharmacist-driven order set with prospective dosing to eliminate
  the reconciliation hold for time-critical anti-infectives? Park to
  Pharmacy Director presentation 2026-05-13.

NEXT MEETING
2026-04-29 · 07:00–08:00 · Auditorium B / Zoom
Pre-reads:  Updated rapid-response activation criteria (Patel)
            MEWS alert build plan (Brooks)
            Credentials Committee response on external peer review

[VERIFY: external-peer-review threshold reference in the medical-staff
bylaws — Credentials Committee to confirm before disposition]

Example 2 — Tumor Board (multidisciplinary, chart-ready recommendation)

Input bullets: 2026-04-23 GI Tumor Board, 90 min, hybrid in-person/Zoom. Facilitator: A. Kim, MD (Surgical Oncology). Scribe: nurse-navigator (P. Lopez, RN, OCN). Attendees: 4 medical oncologists, 2 surgical oncologists, 2 radiation oncologists, 1 GI pathologist (presenting), 2 radiologists, 1 interventional radiologist, 1 genetic counselor, 2 nurse navigators, 1 clinical-trials coordinator. Three cases reviewed; this summary covers the index case. Case: 58M, locally advanced rectal adenocarcinoma cT3N1 MRI-staged 2026-04-15, MMR-proficient, KRAS WT (sequencing pending), CEA 8.4 (2026-04-12), no metastatic disease on PET-CT 2026-04-16. Patient is otherwise healthy, ECOG 0, recently retired teacher. Pathology presented MRI and biopsy slides; radiology re-read confirmed mesorectal fascia not threatened. Discussion: total neoadjuvant therapy (TNT) preferred over selective non-operative management given threatened circumferential resection margin; if complete clinical response, watch-and-wait is acceptable per OPRA-style protocol with patient consent and structured surveillance; trial eligibility: yes for institutional NCT [pending verification]. Genetic counselor noted no Lynch indication on initial screen; universal MMR IHC in place. Consensus: TNT (FOLFOX × 6 followed by long-course chemoradiation, then restaging at 8 weeks post-CRT) with explicit watch-and-wait offer if cCR. Document recommendation in chart and tumor-board note. Action items: Med onc to schedule patient for FOLFOX C1D1 within 14 days; rad onc to consult and consent in parallel; surgical onc to remain treating provider of record and re-engage at restaging; nurse navigator to schedule restaging MRI/sigmoidoscopy/CEA at week 22; genetic counselor to follow up KRAS sequencing result. Open question: clinical-trial enrollment vs. standard TNT — patient preference call after med onc visit.

GI TUMOR BOARD — MULTIDISCIPLINARY CASE CONFERENCE
[Confidentiality: PHI present; use within treatment, payment, and health-
care-operations only — 45 CFR §164.506. Tumor-board recommendation is
intended for the patient's chart; supporting deliberation is not.]

EXECUTIVE SUMMARY
GI Tumor Board reviewed three cases on 2026-04-23. The index case (R.S.,
58M, locally advanced rectal cancer cT3N1, MMR-proficient, M0) was
recommended for total neoadjuvant therapy (TNT): FOLFOX × 6 followed by
long-course chemoradiation, then restaging at 8 weeks post-CRT, with an
explicit watch-and-wait offer if a complete clinical response is
achieved. Med onc to initiate within 14 days; rad onc to consent in
parallel; surgical onc remains provider of record and re-engages at
restaging.

MEETING METADATA
Date / Time:    2026-04-23 · 07:00–08:30
Type:           GI Tumor Board (standing weekly)
Format:         Hybrid (in-person + Zoom)
Facilitator:    A. Kim, MD — Surgical Oncology
Scribe:         P. Lopez, RN, OCN — GI Nurse Navigator
Attendees:      Medical Oncology (4); Surgical Oncology (2);
                Radiation Oncology (2); GI Pathology (1, presenting);
                Diagnostic Radiology (2); Interventional Radiology (1);
                Genetic Counseling (1); Nurse Navigation (2); Clinical
                Trials (1)
Confidentiality: Standard treatment-team conference — not peer-review
                privileged. The tumor-board recommendation copies into
                the patient's chart; supporting discussion does not.

CASE 1 OF 3 — INDEX CASE
Patient identifier (chart-safe form):  R.S. · DOB last 4 /1967 · MRN [last 4]

Clinical question presented:
"What is the optimal sequencing of curative-intent therapy for a
58-year-old man with locally advanced rectal adenocarcinoma cT3N1,
MMR-proficient, M0, ECOG 0, with mesorectal fascia not threatened?"

Tumor Board Recommendation (CHART-READY)
Diagnosis:        Rectal adenocarcinoma, MRI-staged cT3N1, M0 by PET-CT
                  2026-04-16; mesorectal fascia not threatened on
                  radiology re-read 2026-04-23; MMR-proficient on
                  universal IHC.
Recommendation:   Total neoadjuvant therapy (TNT):
                  1) Induction: mFOLFOX6 × 6 cycles
                  2) Consolidation: long-course chemoradiation (50.4 Gy
                     in 28 fx with concurrent capecitabine)
                  3) Restaging at 8 weeks post-CRT (MRI rectum,
                     flexible sigmoidoscopy, CEA)
                  4) If complete clinical response (cCR) on restaging:
                     offer non-operative management (watch-and-wait)
                     with structured surveillance per OPRA-style
                     protocol and patient consent.
                  5) If incomplete response: total mesorectal excision
                     (TME) by surgical oncology.
Pending data that may modify the plan:
                  - KRAS sequencing (out 2026-04-30 per pathology)
                  - Clinical-trial eligibility confirmation (NCT
                    [VERIFY identifier])
Patient-preference notes:
                  Patient preference (rhythm and trial enrollment) to
                  be elicited at the upcoming medical oncology visit.
Provider of record:
                  Surgical Oncology (A. Kim, MD) remains provider of
                  record; medical and radiation oncology are co-
                  managing during the neoadjuvant phase.

Dissent / minority view:
                  None on the global treatment plan. One participant
                  recommended consideration of short-course radiation
                  (5×5 Gy) before chemotherapy as an alternative TNT
                  sequence. Committee consensus held with long-course
                  CRT given comparable efficacy data and the cCR-rate
                  signal favoring long-course in OPRA-aligned cohorts.

Documentation path:
                  This recommendation will be entered as a tumor-board
                  note in the patient's chart by the nurse navigator
                  within 24 hours of the conference and routed to all
                  three treating oncologists, the genetic counselor,
                  and the patient's PCP via secure EHR. The patient
                  will be informed at the medical oncology visit and
                  the recommendation will be the basis of the consent
                  conversation.

ACTION ITEMS (case 1 only — full table covers all three cases)
| # | Action                                                | Owner            | Due       | Status   |
|---|-------------------------------------------------------|------------------|-----------|----------|
| 1 | Schedule patient for med-onc consult; initiate FOLFOX | M. Hernandez, MD | 2026-05-07| Open     |
|   | C1D1 within 14 days of conference                     |                  |           |          |
| 2 | Rad-onc consult and consent in parallel with med-onc  | D. Chen, MD      | 2026-05-07| Open     |
| 3 | Confirm trial eligibility and discuss with patient    | C. Reyes, MA     | 2026-05-07| Open     |
| 4 | Restaging MRI + flex sig + CEA at week 22             | P. Lopez, RN     | 2026-09-22| Open     |
| 5 | Tumor-board chart note routed and acknowledged        | P. Lopez, RN     | 2026-04-24| Open     |
| 6 | Follow up KRAS WT result; modify plan if KRAS-mutant  | M. Hernandez, MD | 2026-04-30| Open     |
| 7 | Confirm Lynch screen disposition (universal IHC neg)  | S. Patel, ScM    | 2026-04-30| Open     |

OPEN QUESTIONS / PARKING LOT
- Confirm institutional clinical trial accrual status for the OPRA-
  successor protocol — verify identifier and slot availability before
  the patient's first med-onc visit.
- Decide watch-and-wait surveillance cadence (q3-mo vs. q4-mo MRI)
  per institutional protocol; defer to the radiology lead's draft
  expected at the 2026-05-07 board.

NEXT MEETING
2026-04-30 · 07:00–08:30 · same hybrid setup
Pre-reads:    new case presentations × 3; OPRA-style surveillance
              cadence draft (Radiology); KRAS result if returned

[VERIFY: institutional clinical-trial NCT identifier and accrual slot
availability before the patient's first medical-oncology consult]

Example 3 — Payer Joint Operating Committee (JOC) (metric-first, no PHI, contractual + operational mix)

Input bullets: 2026-05-14 quarterly JOC, 60 min, hybrid (in-person + Teams). Counterparty: BlueShield Mid-Atlantic Commercial + MA. Practice attendees: R. Iyer (Revenue Cycle Director, chair on practice side); D. Park (Director of Operations); A. Romero, MD (CMO); J. Nguyen (Coding & CDI manager). Payer attendees: K. Mendez (Provider Relations Lead); T. Brooks (UM Medical Director, MD); H. Singh (Network Contracting Manager); one analytics observer. Agenda items: (1) Q1 2026 PA turnaround performance vs. contractual SLA — practice presents an average 4.2 business-day turnaround on commercial PA decisions vs. the contractual 2-business-day SLA, with the commercial musculoskeletal-imaging cohort as the slowest sub-segment; payer concedes vendor migration in February and commits to a written improvement plan by 2026-06-15. (2) Peer-to-peer (P2P) scheduling — practice raises that 38% of P2P requests are scheduled outside the requested 1–4 PM clinical window; payer agrees to add an after-hours block and an asynchronous-P2P pilot. (3) Downcoding trend — practice presents a 14% YoY increase in 99214 → 99213 commercial downcodes for non-procedural office visits; payer denies a policy change and commits to a sample-pull review using six de-identified claim examples (no PHI shared at JOC; claim examples submitted via the secure portal post-meeting). (4) MA risk-adjustment HCC chart-chase support — payer requests practice participation in a Q3 retrospective sweep; practice declines until rate concessions on the commercial fee schedule are re-opened in Q4. (5) CMS-0057-F PA disclosure compliance status — payer confirms January 1, 2026 effective date posture and the AI-decision-reasoning disclosure field on the PA decision letter; no concerns raised. (6) Renewal cycle — current commercial agreement evergreens 2026-12-31; either party may issue a renegotiation notice by 2026-09-30. Open question: whether the practice will exercise the renegotiation notice given the downcoding trend and the PA SLA performance. No PHI at any point in the discussion; case examples handled as aggregate metrics or de-identified claim references. Action items: payer side — written PA improvement plan by 2026-06-15 (K. Mendez); after-hours P2P block live by 2026-07-01 (T. Brooks); sample-pull downcoding review by 2026-07-15 (T. Brooks). Practice side — submit six de-identified claim examples for downcoding review by 2026-05-28 (J. Nguyen); decision on commercial renegotiation notice by 2026-09-15 (R. Iyer + A. Romero); board update on JOC outcomes at the next practice leadership meeting 2026-05-28 (R. Iyer). Confidentiality: routine JOC — no peer-review privilege; no PHI; subject to the BAA and the JOC governance section of the master services agreement.

QUARTERLY JOC — BLUESHIELD MID-ATLANTIC × [PRACTICE NAME]
[Confidentiality: routine JOC governance — no PHI in this summary. Subject
to the BAA dated [VERIFY: BAA effective date] and the JOC governance
section of the master services agreement. NOT peer-review privileged.]

EXECUTIVE SUMMARY
Q1 2026 quarterly JOC reviewed PA turnaround (4.2 business days actual
vs. 2 business-day contractual SLA — payer to deliver a written
improvement plan by 2026-06-15), commercial peer-to-peer scheduling
(38% scheduled outside the requested clinical window — payer to add an
after-hours block and an asynchronous-P2P pilot by 2026-07-01), and
a 14% YoY commercial 99214 → 99213 downcoding trend (payer to run a
sample-pull review on six de-identified claim examples by 2026-07-15).
The practice declined the Q3 MA HCC retrospective-sweep ask pending
commercial-fee-schedule discussions in Q4. The commercial renegotiation-
notice decision is parked for the 2026-05-28 practice leadership meeting.

MEETING METADATA
Date / Time:    2026-05-14 · 13:00–14:00
Type:           Quarterly Joint Operating Committee (standing)
Format:         Hybrid (in-person at practice HQ + Microsoft Teams)
Facilitator:    R. Iyer — Revenue Cycle Director (practice side chair)
Scribe:         J. Nguyen — Coding & CDI Manager
Practice attendees:    R. Iyer (Revenue Cycle Director); D. Park
                       (Director of Operations); A. Romero, MD (CMO);
                       J. Nguyen (Coding & CDI Manager)
Payer attendees:       K. Mendez (Provider Relations Lead);
                       T. Brooks, MD (UM Medical Director);
                       H. Singh (Network Contracting Manager);
                       one analytics observer (non-decision)
Confidentiality: JOC governance — no PHI; subject to BAA and MSA JOC
                section. NOT peer-review privileged. Distribute to
                practice leadership and the payer contract file only.

DECISIONS
1. NO contractual changes made at this meeting. All decisions documented
   below are operational service-level commitments and one parked
   contractual decision.
2. ACCEPTED — Payer commitment to deliver a written PA improvement plan
   covering the musculoskeletal-imaging cohort by 2026-06-15.
3. ACCEPTED — Payer commitment to (a) add an after-hours P2P block
   (16:00–18:00 ET) live by 2026-07-01, and (b) pilot an asynchronous-
   P2P workflow for non-emergent commercial PA reviews, with pilot
   evaluation at the next quarterly JOC.
4. PRACTICE DECLINED — Q3 2026 MA HCC retrospective chart-chase
   participation, pending commercial-fee-schedule discussions in Q4.
   Disposition: revisit at the Q3 quarterly JOC (2026-08-13).
5. PARKED — Commercial renegotiation notice (renewal date 2026-12-31;
   notice deadline 2026-09-30). Practice leadership to decide by
   2026-09-15.

ACTION ITEMS
| # | Action                                                    | Owner               | Due       | Status   |
|---|-----------------------------------------------------------|---------------------|-----------|----------|
| 1 | Submit six de-identified claim examples for downcoding    | J. Nguyen           | 2026-05-28| Open     |
|   | review via the payer secure portal (no PHI in JOC record) |                     |           |          |
| 2 | Deliver written PA-improvement plan (MSK imaging focus)   | K. Mendez (payer)   | 2026-06-15| Open     |
| 3 | Activate after-hours P2P block 16:00–18:00 ET             | T. Brooks (payer)   | 2026-07-01| Open     |
| 4 | Launch async-P2P pilot for non-emergent commercial PAs    | T. Brooks (payer)   | 2026-07-01| Open     |
| 5 | Run downcoding sample-pull review and return findings     | T. Brooks (payer)   | 2026-07-15| Open     |
| 6 | Decide on commercial renegotiation notice for 2026-12-31  | R. Iyer + A. Romero | 2026-09-15| Open     |
| 7 | Brief practice leadership on JOC outcomes and the         | R. Iyer             | 2026-05-28| Open     |
|   | renegotiation-notice decision framing                     |                     |           |          |

DISCUSSION & CONTEXT (non-decision content — aggregate metrics only)
- PA performance: 4.2-business-day average commercial PA turnaround vs.
  the 2-business-day contractual SLA in Q1 2026. Slowest sub-segment
  is commercial musculoskeletal imaging (5.8-day average). Payer
  attributes the variance to a February UM-platform vendor migration
  and commits to a written plan by 2026-06-15.
- P2P scheduling: 38% of P2P requests in Q1 were scheduled outside the
  practice's requested 1–4 PM clinical window. Practice volume: 142
  P2P requests in Q1. Payer agreed to an after-hours P2P block and an
  async-P2P pilot.
- Downcoding trend: 14% YoY increase in commercial 99214 → 99213
  downcodes for non-procedural office visits. Practice will submit
  six de-identified claim examples (no PHI in JOC; via the secure
  portal). Payer denies a policy change; a sample-pull review will
  return by 2026-07-15.
- MA HCC retrospective sweep: Q3 ask declined by practice. Disposition
  contingent on Q4 commercial-fee-schedule discussions.
- CMS-0057-F compliance: payer confirms January 1, 2026 posture; the
  AI-decision-reasoning disclosure field is present on the PA decision
  letter; no concerns raised by either side. The practice's
  `denial-appeal-letter-writer` and `prior-auth-letter-generator` skills
  already accommodate this disclosure pattern.

OPEN QUESTIONS / PARKING LOT
- Whether to exercise the commercial renegotiation notice by 2026-09-30
  given the PA SLA performance and the downcoding trend. Park to the
  practice leadership meeting 2026-05-28.
- Whether to expand the async-P2P pilot to MA after the commercial
  pilot evaluation at the Q3 JOC.
- Whether the MA HCC retrospective ask returns in Q4 as part of the
  fee-schedule discussion or remains contingent on commercial terms.

NEXT MEETING
2026-08-13 · 13:00–14:00 · same hybrid setup (quarterly cadence)
Pre-reads:  Payer PA-improvement plan deliverable (Mendez)
            Async-P2P pilot interim data (Brooks)
            Downcoding sample-pull review findings (Brooks)
            Practice Q2 commercial PA / downcoding metrics (Iyer)

[VERIFY: BAA effective date and MSA JOC governance section reference
before circulating this summary outside the practice leadership and
payer contract file]

The three examples illustrate the target across the most format-sensitive ends of the healthcare-meeting spectrum: an M&M conference where the privilege label, system-and-process framing, and separation between privileged minutes and the safety-event report are load-bearing; a Tumor Board where the recommendation is structured to copy directly into the patient's chart, the dissenting view is recorded, the pending data points that could modify the plan are named, and every action item has a single owner with a date; and a payer JOC where PHI is rigorously excluded, the voice is metric-first, contractual-cycle items (renewal notice deadlines, BAA references, MSA governance sections) are distinguished from operational service items (PA SLA, P2P scheduling, downcoding sample review), and the action-item owners are split cleanly between the payer side and the practice side.